G1 THERAPEUTICS INC (GTHX) Stock News
NASDAQ:GTHX - Nasdaq - US3621LQ1099 - Common Stock - Currency: USD
GTHX Latest News, Press Relases and Analysis
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
/PRNewswire/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84%...
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer...
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
G1 Therapeutics stock is up on Wednesday following news that Pharmacosmos Group is acquiring GTHX for $7.15 per share.
Pharmacosmos Group to Acquire G1 Therapeutics
Pharmacosmos Group to Acquire G1 Therapeutics ...
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
G1 Therapeutics stock is highly volatile, and investors should be wary now as G1 Therapeutics recently failed to achieve a clinical goal.
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes...
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period...
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, OBDC, PETQ on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BAYA, RCFA, OBDC, GTHX on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Kuehn Law Encourages BAYA, RCFA, OBDC, and GTHX Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
Mentions: PETQ
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCM, GTHX, RNST on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
/PRNewswire/ -- Ademi LLP is investigating GI (Nasdaq: GTHX) for possible breaches of fiduciary duty and other violations of law in its transaction with...
GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!
Pharmacosmos Group to Acquire G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024...
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While small-capitalization biotechnology firms bring much potential to the tabl...
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
While there’s no denying that G1 Therapeutics stock is highly speculative, investors should still check under the hood.
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees.
Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
Ginkgo Bioworks layoffs are a hot topic as the company prepares to cut 158 jobs this week with more headcount reductions coming next week.
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
G1 Therapeutics stock is down on Monday as GTHX investors react to the company's Phase 3 clinical trial of trilaciclib failing.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news on Monday morning!